Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.
Papillomavirus Infections
BIOLOGICAL: Gardasil™|BIOLOGICAL: Placebo
Number of Participants Who Seroconvert to HPV 6., Vaccine-induced anti-HPV 6 seroconversion following administration of a 3-dose regimen of GARDASIL® in females 9 to 23 years of age in Korea. Seroconversion for HPV 6 was defined as achieving an anti-HPV cLIA (Competitive Luminex immunoassay) level of at least 20 mMU/mL., Week 4 Postdose 3|Number of Participants Who Seroconvert to HPV 11., Vaccine-induced anti-HPV 11 seroconversion following administration of a 3-dose regimen of GARDASIL® in females 9 to 23 years of age in Korea. Seroconversion for HPV 11 was defined as achieving an anti-HPV cLIA (Competitive Luminex immunoassay) level of at least 16 mMU/mL., Week 4 Postdose 3|Number of Participants Who Seroconvert to HPV 16., Vaccine-induced anti-HPV 16 seroconversion following administration of a 3-dose regimen of GARDASIL® in females 9 to 23 years of age in Korea. Seroconversion for HPV 16 was defined as achieving an anti-HPV cLIA (Competitive Luminex immunoassay) level of at least 20 mMU/mL., Week 4 Postdose 3|Number of Participants Who Seroconvert to HPV 18., Vaccine-induced anti-HPV 18 seroconversion following administration of a 3-dose regimen of GARDASIL® in females 9 to 23 years of age in Korea. Seroconversion for HPV 18 was defined as achieving an anti-HPV cLIA (Competitive Luminex immunoassay) level of at least 24 mMU/mL., Week 4 Postdose 3
Number of Participants With Adverse Experiences, Number of participants who reported 1 or more adverse experience., Overall study including 14 calendar days after the last vaccination visit.
This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.